FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* WOLLAEGER TIMOTHY J			suer Name <b>and</b> Tio				<ol> <li>Relationship of Rep (Check all applicable)</li> <li>X Director</li> </ol>	to Issuer 0% Owner					
(Last) (First) (Middle C/O KINGSBURY ASSOCIATES 4401 EASTGATE MALL	;)		ate of Earliest Tran 27/2006	saction	(Mon	th/Day/Year)			Officer (give below)		Other (specify elow)		
(Street) SAN DIEGO CA 92121		4. If Amendment, Date of Original Filed (Month/Day/Year) 03/01/2006							Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person				
(City) (State) (Zip)			- w										
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Ye	n (ear)	2A. Deemed Execution Date,		ction Instr.			I (A) or	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V		Amount	(A) or (D) Price		Reported Transaction(s) (Instr. 3 and 4)				
Common Stock	02/27/2006	6(1)		J <sup>(2)</sup>		306,436	D	(3)	0	I	By Kingsbury Capital Partners, L.P. III <sup>(4)</sup>		
Common Stock	02/27/2006	6(1)		J <sup>(2)</sup>		40,786	A	(3)	112,905(5)	I	By Timothy J. Wollaeger and Cynthia K. Wollaeger, trustees, U/A DTD 4/25/1985		
Common Stock									685	I	By Kingsbury Associates, L.P. <sup>(4)</sup>		
Common Stock									339,766	I	By Kingsbury Capital Partners, L.P. IV <sup>(4)</sup>		
Common Stock									104,428	I	By Sanderling V Biomedical, L.P. <sup>(6)</sup>		
Common Stock									42,250	I	By Sanderling V Limited Partnership <sup>(6)</sup>		
Common Stock									426,330	I	By Sanderling Venture Partners V, L.P. <sup>(6)</sup>		
Common Stock									37,594	I	By Sanderling V Beteiligungs GmbH & Co. KG <sup>(6)</sup>		
Table I	II - Derivativ	ve Se	ecurities Acq	uired,	Dis	posed of, o	or Ben	eficia	lly Owned				

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of	3. Transaction Ta Date (Month/Day/Year)	Hengeriva Execution Date, if any (e.g., p (Month/Day/Year)	LUTSde Q	ecuri action alls,	tiesu of Wark Secu	anus,	ifedite Figgs Expiration Da QADHOMSy/19	igsecret, ଜନ୍ମvertib	Underl	Writies)	y <sup>8</sup> <b>Owned</b> Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially	10. Ownership Form: Direct (D)	11. Nature of Indirect Beneficial Ownership
1. Title of Derivative Security (Instr. 3)	Derivative Security Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		Acquired FANUMber Prisposed Dermative Resurrings Acquired (A) or		6. Date Exerc Expiration Da (Month/Day/Y	Derivative Security Officers 3 Amount of Securities Underlying Derivative Security (Instr. 3		8. Price of Derivative Security (Instr. 5)	Owned Ponymber of 快好好好 等時以過程的n(s) 肝好時期 Owned Following	or Indirect (1) (Instr. 4) Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	(Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)	
						Dispo of (D) (Instr and 5	sed 3, 4	Date	Expiration	and 4)	Amount or Number of		Reported Transaction(s) (Instr. 4)	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
Explanation	of Respons	es:		Code	<u> </u>	(A)	(D)	Exercisable	Date	Title	Shares Amount or				

- 1. Form 4 amended to correct the transaction date and the date of earliest transaction. The earliest transaction occurred printed by 27, 2006 instead of February 24, 2006 as previously reported.

  2. On 2/24/06, Kingsbury Capital Partners, L.P. III commenced a liquid and edition of the issuer, 63,739 shares of which were received. by the general partner of Kingsbury Capital Partners, L.P. III, Kingsbury Associates, L.P. In turn, Kingsbury Associates, L.P. distributed the 63,739 shares of common stock of the issuer to its partners, 40,786 of which were received by the reporting person. In prior reports, the reporting person reported beneficial ownership of 306,436 shares held by Kingsbury Capital Partners, L.P. III.
- 4. The reporting person is the general partner of Kingsbury Associates, L.P., which is a general partner of each of Kingsbury Capital Partners, L.P. III and Kingsbury Capital Partners, L.P., IV. The reporting person disclaims beneficial ownership of the shares held by Kingsbury Capital Partners, L.P., IV, except to the extent of his pecuniary interests in the named fund. As general partner, the reporting person has voting and investment power with respect to the shares held by Kingsbury Capital Partners, L.P., IV.
- 5. Includes 72,119 shares previously transferred by the reporting person to By Timothy J. Wollaeger and Cynthia K. Wollaeger, trustees, U/A DTD 4/25/1985.
- 6. The reporting person is the managing director of Middleton, McNeil & Mills Associates V, LLC, the general partner of Sanderling Venture Partners V, L.P., Sanderling V Biomedical, L.P., Sanderling V Limited Partnership and Sanderling V Beteiligungs GmbH & Co. KG. The reporting person disclaims beneficial ownership of the shares held by Sanderling Venture Partners V, L.P., Sanderling V Biomedical, L.P., Sanderling V Limited Partnership and Sanderling V Beteiligungs GmbH & Co. KG, except to the extent of his pecuniary interests in the named fund. The reporting person shares voting and investment power with respect to the shares held by Sanderling V enture Partners V, L.P., Sanderling V Biomedical, L.P., Sanderling V Limited Partnership and Sanderling V Beteiligungs GmbH & Co. KG with the other managing directors of Middleton, McNeil & Mills Associates V, LLC.

Vera P. Pardee, by Power of 03/01/2006 Attorney

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.